Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 4Phase 2 3Phase 3 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Carcinoma, Lobular 1Brain Neoplasms 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Interventional × repotrectinib × Clear all
NCT06552234 2026-04-13

REPOROS

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

Phase 2 Recruiting
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06315010 2026-02-25

REPOSE

MedSIR

Phase 2 Recruiting
20 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06408168 2026-01-05

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

M.D. Anderson Cancer Center

Phase 2 Terminated
6 enrolled

Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡